The FDA granted breakthrough therapy designation to an autologous CAR-T cell therapy for pediatric patients with diffuse ...

“At Mustang, we partner with leading academic institutions to advance post-discovery programs toward clinical development ... to the process developed for Mustang’s CAR T cell platform.

Q1 2025 Management View CEO Paul Stoffels highlighted the appointment of Henry Gosebruch as the CEO of SpinCo, marking ...

Immunotherapy Research: Independently design, plan, and execute experiments involving CAR-T cell engineering, optimization, and evaluation using advanced cellular, molecular, and immunological ...

The company is hoping longer follow-up will deliver enough positive trial data on its CRISPR T-cell therapies for blood ...

The U.S. Food and Drug Administration has granted regenerative medicine advanced therapy (RMAT) designation to Fate's FT819 ...

Treating the side effects early can help you recover. If CAR T cell treatment is right for you, your care team collects your T cells with a process called apheresis. Your blood goes through a machine ...

‘#Bloodcancers lead the #CART revolution! #GlobalData reveals they account for over half of all CAR-T therapies in development, with 9 of the top 10 indications. #oncology’ Of the 1,729 CAR-T ...

Additionally, improving CAR-T biological efficiency could reduce dosing needs, further cutting costs and expanding access.

Patients who are already very sick may not wish to endure the side effects associated with CAR-Ts or want to endure the lengthy process where their T-cells are harvested, genetically modified ...

Novartis’ head of drug development Vas Narasimhan talks about the company’s stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions ...